$145.61
+0.82%Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
BDX โข NYSE
| Becton, Dickinson and Company Cash Flow Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | Sep 2007 | Sep 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
1.7B | 1.7B | 1.5B | 1.8B | 2.1B | 874M | 1.2B | 311M | 1.1B | 976M | 695M | 1.2B | 929M | 1.1B | 1.3B | 1.2B | 1.2B | 1.1B | 890M | 815.1M | |
2.5B | 2.3B | 2.3B | 2.2B | 2.3B | 2.2B | 2.3B | 2B | 1.1B | 1.1B | 891M | 562M | 546M | 510.9M | 504.1M | 502.1M | 470.2M | 477.4M | 441.3M | 405.1M | |
-474M | -211M | -622M | -120M | -304M | -302M | -381M | -240M | -236M | -426M | -336M | -32M | 36M | 22.1M | 30M | 28.1M | 60M | 80.1M | -115.5M | -108.3M | |
258M | 247M | 259M | 233M | 229M | 236M | 261M | 322M | 174M | 196M | 166M | 113M | 100M | 89M | 73.4M | 79.4M | 86.6M | 100.6M | 0.0 | 0.0 | |
306M | -522M | 164M | -94M | 75M | 65M | 120M | -403M | 795M | 300M | 39M | 33M | -52M | 32M | 96.9M | 27.1M | -23.3M | 44.5M | 190.4M | 119.3M | |
-800M | 293M | -630M | -1.4B | 282M | 512M | -143M | 897M | -371M | 399M | 274M | -117M | 160M | -3.5M | -253.3M | -68.8M | -89.7M | -87.3M | -165.9M | -154.8M | |
3.4B | 3.8B | 3B | 2.6B | 4.6B | 3.5B | 3.3B | 2.9B | 2.6B | 2.6B | 1.7B | 1.7B | 1.5B | 1.8B | 1.7B | 1.7B | 1.7B | 1.7B | 1.2B | 1.1B | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-760M | -725M | -874M | -973M | -1.2B | -810M | -957M | -895M | -727M | -718M | -633M | -653M | -588M | -553.6M | -605.3M | -632.5M | -700.7M | -651.3M | -578.7M | -482.1M | |
(0.0) | -3.9B | (540M) | -2.1B | -508M | -164M | (477M) | -14.7B | -9M | (158M) | -8.4B | -40M | (600M) | -103.4M | -492.1M | -21.4M | (51M) | -41.3M | -339.5M | -231.5M | |
(0.0) | -421M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (895M) | (727M) | -1M | (633M) | -171M | -225M | -137.9M | (514.8B) | (963M) | -338.2M | -52M | -34M | -28.3M | |
422M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11M | 13M | 718M | 840M | 653M | 0.0 | 486.9B | 121.6M | 535.7B | 840K | 0.0 | 20M | 0.0 | |
-480M | -444M | -382M | -188M | -141M | -258M | -261M | -1.1B | -887M | -826M | -744M | -737M | -310M | -487B | -514.8B | -536.8B | -85.9M | -38.5M | -85.9M | -44.7M | |
-818M | -5.5B | -716M | -3.2B | -1.9B | -1.2B | -741M | -15.8B | -883M | -669M | -8.3B | -948M | -523M | -900.1M | -1B | -705.6M | -1.1B | -783M | -1B | -786.5M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-1B | -500M | 0.0 | -500M | -1.8B | 2.9B | 0.0 | 0.0 | 4.6B | -32M | 0.0 | -409M | -406M | -1.5B | -1.4B | -699.9M | -517.6M | -364.6M | -319.4M | -301.1M | |
-1.3B | 3.8B | -722M | -78M | -243M | -1.8B | -2B | 1.1B | 7.3B | -1.3B | 6.7B | -4M | -199M | 1.4B | 1B | -200.3M | 740.1M | -7.1M | -221.9M | 120.7M | |
-1.2B | -1.1B | -1.1B | -1.1B | -1B | -1B | -984M | -927M | -677M | -562M | -485M | -421M | -386M | -367.6M | -361.2M | -345.7M | -316.9M | -278.5M | -239.8M | -212.4M | |
-1B | -500M | (0.0) | -500M | -1.8B | (0.0) | (0.0) | (0.0) | -220M | -32M | (0.0) | -400M | -450M | -1.5B | -1.5B | -750M | -550M | -450M | -450.1M | -448.9M | |
-87M | -88M | -121M | 1.1B | -265M | -109M | -204M | -220M | -234M | 85M | 20M | 27M | 23M | 14.9M | 37.2M | 23.2M | 14.7M | 64.3M | 55.1M | 50.6M | |
-3.6B | 2.1B | -2B | -591M | -3.3B | 22M | -3.2B | -57M | 11B | -1.8B | 6.2B | -807M | -968M | -370.2M | -714.4M | -1.2B | -79.7M | -585.8M | -726M | -342.2M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 4M | 5M | -45M | 15M | -3M | -12M | -17M | -6M | -12M | -38M | -20M | -7M | 5.9M | -2.8M | 5.8M | -390K | 748K | 15M | 9.7M | |
-1B | 375M | 322M | -1.2B | -525M | 2.3B | -646M | -13B | 12.6B | 117M | -437M | -29M | 219M | 495.9M | -40.7M | -178.3M | 563.8M | 319M | -488.8M | -42.6M | |
1.9B | 1.5B | 1.2B | 2.4B | 2.9B | 590M | 1.2B | 14.2B | 1.5B | 1.4B | 1.9B | 1.9B | 1.7B | 1.2B | 1.2B | 1.4B | 830.5M | 511.5M | 1B | 1B | |
851M | 1.9B | 1.5B | 1.2B | 2.4B | 2.9B | 590M | 1.1B | 14.2B | 1.5B | 1.4B | 1.9B | 1.9B | 1.7B | 1.2B | 1.2B | 1.4B | 830.5M | 511.5M | 1B | |
2.7B | 3.1B | 2.1B | 1.7B | 3.4B | 2.7B | 2.4B | 2B | 1.8B | 1.8B | 1.1B | 1.1B | 919M | 1.2B | 1.1B | 1.1B | 1B | 1B | 661.7M | 594.3M |
BDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 20, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | May 07, 2026 | October 09, 2025 | 2025 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 |
Continue your BDX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.